Theodore Karrison to Prognosis
This is a "connection" page, showing publications Theodore Karrison has written about Prognosis.
Connection Strength
0.347
-
Modeling major lung resection outcomes using classification trees and multiple imputation techniques. Eur J Cardiothorac Surg. 2008 Nov; 34(5):1085-9.
Score: 0.047
-
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977.
Score: 0.031
-
Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17.
Score: 0.030
-
Sizes of ruptured and unruptured aneurysms in relation to their sites and the ages of patients. J Neurosurg. 2002 Jan; 96(1):64-70.
Score: 0.030
-
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
Score: 0.027
-
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019 08; 186(4):549-560.
Score: 0.025
-
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 02 01; 30(2):297-302.
Score: 0.024
-
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer. 2019 05 15; 125(10):1629-1636.
Score: 0.024
-
Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. Mod Pathol. 2018 04; 31(4):598-606.
Score: 0.023
-
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8.
Score: 0.015
-
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46.
Score: 0.014
-
Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol. 2007 Feb; 127(2):197-205.
Score: 0.011
-
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res. 2004 May 15; 10(10):3365-70.
Score: 0.009
-
Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol. 2003 Oct; 170(4 Pt 1):1141-5.
Score: 0.008
-
The pathological findings of breast cancer in patients surviving 25 years after radical mastectomy. Cancer. 1982 Nov 15; 50(10):2131-8.
Score: 0.008
-
Delta F508 genotype does not predict disease severity in an ethnically diverse cystic fibrosis population. Pediatrics. 1994 Jan; 93(1):114-8.
Score: 0.004
-
Localized prostate cancer: use of serial prostate-specific antigen measurements during radiation therapy. Radiology. 1992 Jul; 184(1):271-4.
Score: 0.004
-
Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast. Cancer. 1987 May 15; 59(10):1744-50.
Score: 0.003
-
Histologic features associated with long-term survival in breast cancer. Hum Pathol. 1986 Oct; 17(10):1015-21.
Score: 0.003
-
Fast walking velocity in health and Duchenne muscular dystrophy: a statistical analysis. Arch Phys Med Rehabil. 1984 Oct; 65(10):573-8.
Score: 0.002
-
Staging of breast cancer and survival rates. An assessment based on 50 years of experience with radical mastectomy. JAMA. 1982 Sep 17; 248(11):1337-41.
Score: 0.002
-
Prognostic significance of immunological tests in lung cancer. Clin Exp Immunol. 1981 Feb; 43(2):362-9.
Score: 0.002